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ABSTRACT  
Objective: Objective of the present analytical research work was to develop and validate Spectrophotometric method and High Performance 
Liquid Chromatographic method (HPLC Method) for the Apremilast bulk and tablets dosage form. 
Methods: A spectrophotometric method and a HPLC method have been developed and validated for estimation of APR in pharmaceutical oral 
dosage form. 
Method A (UV SPECTROMETRY Method): The stock and working standard solutions of the drugs were prepared in methanol. Standard 
solutions were scanned over the range of 400-200 nm in spectrum mode of spectrophotometer at medium scanning speed using UV 
spectrophotometer. The maximum absorbance for Apremilast was found at 230 nm.  
Method B (HPLC Method): The HPLC Method for Apremilast was developed using Cosmosil C18 (4.6mm x 250mm, Particle size: 5µm), as 
stationary particle, isocratic mode. Methanol: Water (80:20v/v) pH3 as mobile phase. Mobile phase was maintained at a flow rate of 0.8 
ml/min and detection was carried out at 230 nm. Both the methods were validated in accordance with ICH guidelines 
Results: Apremilast was found to be linear in the concentration range of 2-10 µg/ml for spectrophotometric method and 10-50 µg/ml for HPLC 
method. Retention time was found to be 4.0 min for Apremilast. The amount of Apremilast in marketed formulation by spectrophotometric 
method was found to be 99.82 %, the amount of Apremilast in marketed formulation by HPLC method was found to be 99.98 %. 
Interpretation and Conclusion: Results of assay and validation study were found to be satisfactory. So, the methods can be successfully 
applied for the routine analysis of Apremilast. 
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INTRODUCTION 
According to recent study no treatment can cure psoriasis 
but Apremilast can control signs and symptoms of psoriasis. 
Apremilast is a class of phosphodiester-4 inhibitor used in 
treatment of rheumatic arthritis and psoriatic arthritis. It is 
act as an anti-inflammatory caused by these conditions. 
Phosphodiesterase inhibitor is a cyclic adenosine 
monophosphate which is predominantly located in 
inflammatory cells and by inhibiting PDE-4 it increases intra-
cellular level of cAMP which further inhibits pro-
inflammatory mediators including interleukin-2, interferon 
gamma, TNF-alpha, PDE-4.  
 
Figure 1: Structure of Apremilast 
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By chemically Apremilast is N-[2-[(1S)-1-(3-ethoxy-4-
methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-
dioxo-1H-isoindol-4-yl]acetamide with molecular formula 
and weight of C22H24N2O7S and 460.5 g/mole respectively. 
This analysis method follows ICH validation guidelines. This 
current research tries to develop new rapid, effective method 
for determination of Apremilast in bulk form according to 
ICH Q2 R1 guidelines. 
MATERIALS AND METHODS 
Chemicals and Reagents  
Analytically pure samples of Apremilast were kindly supplied 
by Hetero Drugs Limited., Water (HPLC Grade) and MeOH 
(AR grade ) Merck specialities private limited, Mumbai 
Instrument Used 
Electronic Weighing Balance (Shimadzu AY-220),  
Ultrasonicator  (Wenser pvt ltd  PGB-100), Cellulose Acetate 
Filter, 0.45 µm (Nylon 66), HPLC System (Analytical 
Technologies),UV VIS Spectrophotometer (Shimadzu  UV-
1800) 
1. Spectrophotometric Method 
1.1 Development of Spectrophotometric  Method 
Selection of Solvent 
Solutions  of  APR  (1000  µg/ml)  was  prepared  in different 
solvents like methanol and water. These solutions were 
scanned in UV-Visible Region (200 nm to 800 nm) and 
intensity of absorption and wavelength of absorption were 
studied. 
Preparation of Standard Stock Solution 
Standard stock solution was prepared. 
Selection of Wavelength Range 
From the stock solutions, 0.1 ml of APR was transferred to 10 
ml volumetric flask and the volume was  adjusted  to  the  
mark  with  MeOH  to  obtain Strength 10µg/ml. The solution 
was scanned in the UV range 200-400 nm. 
 
Fig 2. UV spectra of Apremilast 
Preparation for Calibration Curve 
Calibration curve were prepared and graph was plotted. 
Analysis of Tablets 
For   analysis  of   commercial  formulation,  twenty tablets 
were weighed, average weight determined and crushed  into  
fine  powder.  An  accurately  weighed quantity of powder 
equivalent to 10 mg of APR was transferred into 10 ml 
volumetric flask containing 5 ml methanol, shaken manually 
for 10 min, volume was adjusted to mark with same solvent 
and filtered  through  Whatman filter  paper. The absorbance  
of   sample  solution was   recorded  at recorded at 230 nm. 
1.2. Validation of Spectrophotometric Method 
Linearity and Range 
The  linearity  of  analytical  method  for  APR  was 
determined by studying standard calibration curves. The 
range of analytical method was decided from the interval 
between upper and lower level of calibration curves by 
plotting the log curve. 
Accuracy 
Accuracy of the method was assessed by standard addition 
method  at  three  different  concentration levels  i.e.  50%,  
100,  150. Standard concentration of 2,4, and 6 µg/ml was 
added into 4 µg/ml of tablet concentration. The % recovery 
was then calculated by using formula  
% Recovery = A – B/ C, 
Where, 
A = Total amount of drug estimated 
B = Amount of drug found on pre analysed basis 
C = Amount of Pure drug added 
Precision 
The precision of an analytical method was studied by 
performing intermediate precision. 
Intra-day Precision 
Intra-day precision was determined by analyzing the 2,4,6 
µg/ml of APR for three times in the same day. 
Inter-day Precision 
Inter-day precision was determined by measuring the the 
2,4,6 µg/ml of APR for three consecutive days. 
Limit of Detection (LOD) and Limit of Quantitation (LOQ) 
Detection    limit    and    quantitation    limit    were 
determined  based  on  the  standard  deviation  of  y-
intercepts of calibration curves and average slope of 
calibration curves. 
LOD = 3.3 × Standard deviation of intercept 
                 Slope 
LOD = 10× Standard deviation of intercept 
                 Slope 
 Ruggedness 
Ruggedness  of  the  method  was  checked  by  two 
different  analysts  keeping  same  experimental  and 
environmental conditions.  An  appropriate concentration  
4,8  µg/ml  of  APR  was  subjected  to analysis  and  
concentration  was  determined.  This procedure was 
repeated three times. 
2. Chromatographic Method 
2.1. Development of Chromatographic method 
Description 
The sample of Apremilast was observed for its color and 
texture. 
Solubility 
The sample of Apremilast was taken in test tubes and 
observed for solubility in various solvents like alcohol  and 
water. 
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Selection of Mobile Phase 
The  selection was  made  on  the  basis  of  literature  
survey. After assessing the solubility of drug in different 
solvents as well on the basis of literature survey, Methanol 
and water were selected as a first choice. 
Selection of Analytical Wavelength 
To   investigate   the   appropriate   wavelength   for 
determination of APR, the solution of the same in the MeOH 
were scanned separately by UV–Visible spectrophotometer 
in the range of 190-400 nm and the spectrum were recorded. 
Preparation of Mobile Phase 
Mobile Phase A: HPLC grade MeOH was degassed in 
sonicator for 15 min. 
Mobile Phase B: HPLV grade water 
Preparation of Standard Stock Solution 
Standard stock solution was prepared by dissolving 10  mg  
of Apremilast  in  10  ml  methanol  that  gives concentration 
of 1000  g/ml of Apremilast and labeled as Standard stock 
Apremilast. 
Preparation of Calibration Curve  
Analysis of tablets 
To  determine  the  content  of  APR  in  conventional tablets; 
the twenty tablets were weighed, their mean weight 
determined and they were finely powered and powder 
equivalent 10.0 mg APR was transferred into a 10 mL 
volumetric flask containing 5 mL methanol, sonicated for 30 
min  and  diluted  to  1000  mL  with  methanol. The resulting 
solution  was  filtered,  using 0.22 µm filter and 30 µg/mL 
was injected into system. The amount of APR was 
determined. The assay procedure was repeated for six times 
and Calculated using following equation. 
Ct= Rt × Cs 
     Rs 
Where, Ct and Cs = Concentration of Sample and Standard 
Solution, respectively.   Rt and Rs = Peak Area for Sample and 
Standard Solution, respectively. 
2.2 Validation of HPLC Method 
 Linearity  
The linearity of analytical method  for  APR  was determined 
by studying standard calibration curves. The range of 
analytical method was decided from the interval between 
upper and lower level of calibration curves by plotting the 
log curve. 
Accuracy 
Accuracy of the method was assessed by standard addition  
method  at  three  different  concentration levels i.e. 50%, 
100, 150%. Standard concentration of 10,20 and 30 µg/ml 
was added into 20 µg/ml of tablet concentration. The % 
Recoveries was calculated by applying regression equation. 
Precision 
The precision of an analytical method was studied by 
performing intermediate precision. 
Intra-day Precision 
Intra-day precision was determined by analyzing the 
standard solutions of APR (10,30,50 µg/ml) and at three 
different time intervals on same day. 
Inter-day Precision 
Inter-day precision was determined by analyzing the 
combined standard solution of Apremilast (10,30,50  µg/ml) 
on three consecutive days. The results were reported in 
terms of % RSD. 
Limit of Detection and Limit of Quantitation 
 Detection    limit    and    quantitation    limit    were 
determined  based  on  the  standard  deviation  of  y-
intercepts of calibration curves and average slope of 
calibration curves. 
LOD = 3.3 × Standard deviation of intercept 
         Slope 
LOD = 10× Standard deviation of intercept 
          Slope 
Robustness 
Standard solution of APR (30 µg/ml)) were used and 
analyzed at different flow rate (0.7,0.8,0.9 ml/min) and 
wavelength (228,230,232 nm). 
Ruggedness 
Ruggedness of the method was checked by two different 
analysts keeping same experimental and environmental 
conditions. An appropriate concentration 30 µg/ml of APR 
was subjected to analysis and concentration was determined. 
This procedure was repeated three times. 
 System Suitability 
Standard solution of APR (30 µg/ml) was prepared and 
analyzed. Chromatograms were studied for different 
parameters such as tailing factor, resolution and theoretical 
plates to see that whether they complies with the  
recommended limit or not. 
RESULT AND DISCUSSION 
1. UV-Visible Spectrophotometric Methods 
Linearity study 
Standard solution having concentration range of 2,4,6,8,10 
µg/ml of APR was prepared. Absorbances  of  these  
solutions  were  recorded  at 230 nm. Calibration curve was 
plotted, absorbance vs concentration. Fig 3, Table 1. 
 
Fig 3. Calibration curve by UV 
Table 1. Data of calibration curve by UV 
Sr. No. Conc. (µg/mL) Absorbance 
1 2 0.4069 
2 4 0.7786 
3 6 1.1225 
4 8 1.4916 
5 10 1.9151 
 
y = 0.1865x + 0.0241 
R² = 0.9987 
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Badhe et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2019; 9(6-s):136-142 
ISSN: 2250-1177                                                                                  [139]                                                                                 CODEN (USA): JDDTAO 
Table 2. linear regression analysis by UV 
Sr.No Parameters Zero Order spectrophotometric method 
1 λmax (nm) 230 
2 Beer's law limit (μg/mL) 2-10 
3 Regression equation[y] y = 0.1865x + 0.0241 
4 Slope[m] 0.1865 
5 Intercept [c] 0.0241 
6 Correlation coefficient [r2 ] 0.9987 
7 Limit of detection (LOD) (μg/mL) 0.0424 
8 Limit of quantitation (LOQ) (μg/mL) 0.1286 
 
Assay of Marketed Formulation 
Using   this   method,   the   marketed   formulation was 
analyzed. Sample solution containing 6 µg/ml. The amount 
of drug   present   in   the   marketed   formulation   was 
calculated .The mean % assay of APR was found to be 
99.82%. Table 3. 
 
Table 3. Result of tablet analysis 
Drug Name Mean* SD %RSD 
Otezla 99.82 1.0586 1.06 
 
Validation Parameters 
Validation   of   the   method   was   performed   in accordance  
to  ICH  guidelines.  Accuracy  of  the method  was  
determined at  50%,  100%  and  150% level by standard 
addition method and percentage recovery APR were found 
to be in the range of 99.93 – 100.29 %. Precision of the 
method was determined by % RSD of intra-day precision, 
inter-day precision. It was found to be less LOD and LOQ of 
APR was found to be 0.0424 and 0.1286 µg/ml, respectively.
 
Table 4. Result of Accuracy study 
Level of addition % Mean recovery* SD % RSD 
50% 100.22 0.2553 0.25 
100% 100.29 0.1931 0.19 
150% 99.93 0.1154 0.11 
 
Table 5A. Result of intraday precision 
Sr.No Conc. (μg/mL) Absorbance Mean SD %RSD 
1 2 0.4051  
 
0.4043 
 
0.0030 
 
0.74 2 2 0.4069 
3 2 0.4010 
4 4 0.7769 
0.7759 0.0032 0.42 5 4 0.7786 
6 4 0.7723 
7 6 1.1236 
1.1253 0.0039 0.34 8 6 1.1225 
9 6 1.1298 
 
Table 5B. Result of interday precision 
Sr.No Conc. (μg/mL) Absorbance Mean SD %RSD 
1 2 0.4036  
 
0.4067 
 
0.0031 
 
0.76 2 2 0.4069 
3 2 0.4098 
4 4 0.7726 
0.7758 0.0030 0.39 5 4 0.7786 
6 4 0.7763 
7 6 1.1253 
1.1239 0.0014 0.12 8 6 1.1225 
9 6 1.1241 
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Table 6A. result of robustness study 
Parameters Change In   Wavelength(±2 nm) 
Wavelength (228nm) Wavelength (232nm) 
 4 ppm 8 ppm 4 ppm 8 ppm 
Mean(n=3) 0.7761 1.4908 0.7774 1.4902 
SD 0.0007 0.0006 0.0001 0.0016 
% RSD 0.1917 0.0988 0.4818 0.2634 
 
Table 6B. result of robustness study 
Parameters Change In   Solvent 
Water 0.1N NaOH 
 4 ppm 8 ppm 4 ppm 8 ppm 
Mean(n=3) 0.7765 1.4910 0.7763 1.4895 
SD 0.00079 0.0015 0.0006 0.0008 
% RSD 0.250 0.3614 0.2086 0.2091 
 
Table 7. result of ruggedness study 
Parameters Change in Analyst 
Analyst I Analyst II 
 4ppm 8ppm 4ppm 8ppm 
Mean(n=3) 0.7784 1.4932 0.7769 1.4920 
SD 0.0006 0.0008 0.0011 0.0006 
% RSD 0.2807 0.2076 0.5467 0.1460 
 
2. Chromatographic Method 
Selection of Analytical Wavelength 
The standard solutions of APR (10 µg/ml) in mobile phase 
were scanned in the UV region of 190 - 400 nm and  the  
overlain  spectra  were  recorded.  It  was observed that APR 
drugs showed the absorbance at 230 nm. So, the wavelength 
of detection used was 230 nm. 
Mobile phase 
Methanol : Water (80:20v/v) 
pH3 
Selection of column 
Cosmosil C18 (4.6mm x 250mm, 
Particle size: 5µm) 
Injection volume 20 μL 
Flow rate 0.8 ml/min 
Column temperature Room Temperature 
Detection 
wavelength 
230nm 
Retention time 4.0 min 
 
 
Figure 4. Typical chromatograph of Apremilast by HPLC 
at Optimized condition 
 
Linearity Study 
APR was found to be linear in the concentration range of 10-
50 µg/ml. Fig 5, Table 8 and Table 9 
 
Fig 5. calibration curve by HPLC 
Table 8. Result of calibration curve 
Sr. No. Conc. (μg/ml) Area 
1 10 614839 
2 20 1339880 
3 30 2032564 
4 40 2665713 
5 50 3251263 
 
Table 9. Linear regression analysis 
S.N. Parameters HPLC method 
1 λmax (nm) 230 
2 Beer's law limit (μg/mL) 10-50 
3 Regression equation[y] y = 65987x + 1247.5 
4 Slope[m] 65987 
5 Intercept [c] 1247.5 
6 Correlation coefficient [r2 ] 0.9981 
7 Limit of detection (LOD) 
(μg/mL) 
0.1646 
8 Limit of quantitation (LOQ) 
(μg/mL) 
0.4988 
 
y = 65987x + 1247.5 
R² = 0.9981 
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Assay of Marketed Formulation 
Amount of drugs present in the marketed formulation 
equations. Amount of APR found in the range from 99.99% 
and SD ± 0.015. Table 10 
Table 10. Assay result by HPLC 
Drug Name Mean* SD %RSD 
Otezla 99.98 0.0605 0.06 
 
Validation Parameters 
This  method  was  validated  in  accordance  to  ICH 
guidelines.  Percentage  of  recoveries  of  APR  was found in 
the range from 98.65 – 101.69%. Precision of the method 
was determined by % RSD found among intra-day precision, 
inter-day precision. LOD and LOQ of APR were found to be 
0.1646 and 0.4988 µg/ml, respectively. For robustness study, 
the effect of change in wavelength and flow rate ( ± 0.1 
ml/min) on the Mean peak area, % RSD and % Assay were 
studied. Percentage RSD  of  each  peak  in  all variables was 
found to be less than 2 %. Table 11,12A,12B,13,14,15. 
Table 11. Result of Accuracy by HPLC 
Level of addition % Mean recovery* SD % RSD 
50% 99.99 0.1795 0.17 
100% 100.06 0.3547 0.35 
150% 100.07 0.1026 0.10 
 
 
Table  12A. Result of intraday precision 
Sr. No. Conc. (μg/mL) Area Mean SD %RSD 
1 10 614839       
615216 525.86 0.08 2 10 615817         
3 10 614993         
4 30 2032564       
2033124 3313.68 0.16 5 30 2030126        
6 30 2036682        
7 50 3251263       
3252790 3500.16 0.10 8 50 3256795       
9 50 3250314       
 
Table 12B Result of Interday precision 
Sr. No. Conc. (μg/mL) Area Mean SD %RSD 
1 10 614839       
614901 1283.14 0.20 2 10 613651         
3 10 616215       
4 30 2032564       
2034800 3325.05 0.16 5 30 2033215        
6 30 2038621        
7 50 3253512       
3254106 2445.83 0.07 8 50 3256795       
9 50 3252013      
 
 
Table 13. Result of robustness study 
Sr.No Parameter Condition Area Mean SD %RSD 
1  
 
 
 
Change in 
Flow rate 
(ml/min) 
0.7 1333913  
 
 
3024.58 0.22 2 0.8 1339880 1337183 
3 1.0 1337757  
1  228 1340385  
 
 
896.26 0.06 2 Change in Wavelength 
(nm) 
230 1339880 1340629 
3  232 1341622  
 
 
Table 14. Result of Ruggedness 
Sr.No Analyst Conc. (μg/ml) Mean area* SD % RSD 
1 Analyst-Ι 30 2033124 
 
3313.68 0.16 
2 Analyst-ΙΙ 30 2035415 
 
1083.08 0.05 
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Table 15. Result of system Suitability 
Sr. No. conc. (μg/ml) 
Retention 
Time/min 
Theoretical plates Asymmetry Factor 
1 30 4.0 8988 1.25 
2 30 4.0 8897 1.25 
3 30 4.0 8709 1.25 
4 30 4.0 8685 1.25 
5 30 4.0 8479 1.24 
6 30 4.0 8900 1.24 
Mean 
 
4.00 8859.66 1.246 
SD 0.00 131.86 0.0051 
%RSD 0.00 1.48 0.41 
 
CONCLUSION 
In the present investigation, the developed and validated,   
UV   Spectrophotometric  method were found to be simple, 
economical and rapid method. HPLC was  found  to  more  
precise,  accurate, rugged and robust for determination of 
Apremilast. The excipients usually present in the 
pharmaceutical formulation did not interfere with 
determination of Apremilast. Developed method can be 
successfully used in laboratory to measure the 
concentration of API  in  specific dosage form.  This  
method is  also beneficial for the formulation and 
development department. These methods are always useful 
for analysis, purity testing and assay. The consumption of 
time and chemicals is less as compare to other tedious 
method. This is new concept for the validation of method 
development and method transfer in pharmaceutical 
companies. The results and the statistical parameters 
demonstrate that the proposed UV spectrophotometric and 
HPLC method is simple, rapid, specific, accurate and precise. 
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